Last April Qurin Diagnostics B.V. and Lionix International B.V. have acquired Surfix B.V. These companies work together closely on early cancer detection and have realized a sensitive biochip, bringing together their respective complementary technologies for this purpose. This acquisition strengthens their relationship and mutual commitment towards bringing this technology to the global biomedical market.
An interview about this platform and its future applications, not just for cancer diagnostics, has been published in ‘360dx’ that publishes articles covering emerging economic and technological trends in the clinical diagnostic market.
The complete article can be read here.